Literature DB >> 7982234

Depressed immunity and the development of cancer.

I Penn1.   

Abstract

Various disorders of immune competence are associated with increases in uncommon tumors, particularly non-Hodgkin's lymphomas (NHLs), which often exhibit unusual features: they are frequently extranodal, show a broad spectrum of lesions, ranging from benign polyclonal hyperplasia to frankly malignant monoclonal lymphomas, and are frequently localized to the brain. Of 7136 tumors in organ transplant recipients, the predominant lesions are NHLs, carcinomas of the skin and lips, carcinomas of the vulva/perineum, Kaposi's sarcoma (KS), and renal carcinomas. Skin cancers present unusual features: predominance of squamous cell carcinomas, young age of the patients, and a high incidence of multiple tumors. Cancers of the vulva/perineum occur at a much younger age than in the general population. In AIDS patients the most common malignancy is KS, which occurs in 14%, whereas NHLs afflict 2.9%. A variety of other tumors occur in these patients. The most common tumors in patients with primary immunodeficiency states are NHLs (49%), leukemias (13%), various carcinomas (9%), and Hodgkin's disease (7%).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982234

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  15 in total

1.  Epstein-Barr virus in malignancies in renal transplant recipients in Japan.

Authors:  Y Hoshida; Y Tomita; M Ohsawa; X Ning; K Aozasa
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  On the crossroad between tolerance and posttransplant lymphoma.

Authors:  Michael A Nalesnik; Thomas E Starzl
Journal:  Curr Opin Organ Transplant       Date:  1997-10-01       Impact factor: 2.640

Review 3.  The association between atopy and childhood/adolescent leukemia: a meta-analysis.

Authors:  Amy M Linabery; Anne M Jurek; Sue Duval; Julie A Ross
Journal:  Am J Epidemiol       Date:  2010-03-12       Impact factor: 4.897

4.  Unusual aggressive course of a giant cell tumor of soft tissue during immunosuppressive therapy.

Authors:  Florian Grabellus; Friederike von Winterfeld; Sien-Yi Sheu; Klaus A Metz; Klaus Jahnke; Kurt W Schmid
Journal:  Virchows Arch       Date:  2006-04-05       Impact factor: 4.064

5.  Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.

Authors:  Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic; Andrew E Grulich
Journal:  BMJ       Date:  2010-02-11

6.  Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis.

Authors:  Chi-Shan Li; Chong Chen; Pan Zheng; Yang Liu
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

7.  Mutagenic and cytotoxic properties of 6-thioguanine, S6-methylthioguanine, and guanine-S6-sulfonic acid.

Authors:  Bifeng Yuan; Yinsheng Wang
Journal:  J Biol Chem       Date:  2008-06-30       Impact factor: 5.157

8.  Are We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years' Experience.

Authors:  Mehmet Turkeli; Melih Simsek; Mehmet Naci Aldemir; Nilgun Yildirim; Erdem Cankaya; Burak Erdemci; Mehmet Bilici; Salim Basol Tekin; Sukru Arslan; Ercan Korkut
Journal:  Eurasian J Med       Date:  2016-02

9.  Exosomes as a tumor immune escape mechanism: possible therapeutic implications.

Authors:  Thomas E Ichim; Zhaohui Zhong; Shalesh Kaushal; Xiufen Zheng; Xiubao Ren; Xishan Hao; James A Joyce; Harold H Hanley; Neil H Riordan; James Koropatnick; Vladimir Bogin; Boris R Minev; Wei-Ping Min; Richard H Tullis
Journal:  J Transl Med       Date:  2008-07-22       Impact factor: 5.531

10.  In vitro replication and thermodynamic studies of methylation and oxidation modifications of 6-thioguanine.

Authors:  Chunang Gu; Yinsheng Wang
Journal:  Nucleic Acids Res       Date:  2007-05-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.